724 related articles for article (PubMed ID: 20962567)
1. Genetic markers and danger signals in stevens-johnson syndrome and toxic epidermal necrolysis.
Chung WH; Hung SI
Allergol Int; 2010 Dec; 59(4):325-32. PubMed ID: 20962567
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in the genetics and immunology of Stevens-Johnson syndrome and toxic epidermal necrosis.
Chung WH; Hung SI
J Dermatol Sci; 2012 Jun; 66(3):190-6. PubMed ID: 22541332
[TBL] [Abstract][Full Text] [Related]
3. Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome.
Ko TM; Chung WH; Wei CY; Shih HY; Chen JK; Lin CH; Chen YT; Hung SI
J Allergy Clin Immunol; 2011 Dec; 128(6):1266-1276.e11. PubMed ID: 21924464
[TBL] [Abstract][Full Text] [Related]
4. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population.
Tassaneeyakul W; Jantararoungtong T; Chen P; Lin PY; Tiamkao S; Khunarkornsiri U; Chucherd P; Konyoung P; Vannaprasaht S; Choonhakarn C; Pisuttimarn P; Sangviroon A; Tassaneeyakul W
Pharmacogenet Genomics; 2009 Sep; 19(9):704-9. PubMed ID: 19696695
[TBL] [Abstract][Full Text] [Related]
5. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs.
Lonjou C; Borot N; Sekula P; Ledger N; Thomas L; Halevy S; Naldi L; Bouwes-Bavinck JN; Sidoroff A; de Toma C; Schumacher M; Roujeau JC; Hovnanian A; Mockenhaupt M;
Pharmacogenet Genomics; 2008 Feb; 18(2):99-107. PubMed ID: 18192896
[TBL] [Abstract][Full Text] [Related]
6. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis.
Chung WH; Hung SI; Yang JY; Su SC; Huang SP; Wei CY; Chin SW; Chiou CC; Chu SC; Ho HC; Yang CH; Lu CF; Wu JY; Liao YD; Chen YT
Nat Med; 2008 Dec; 14(12):1343-50. PubMed ID: 19029983
[TBL] [Abstract][Full Text] [Related]
7. HLA-B*1502 strongly predicts carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Thai patients with neuropathic pain.
Kulkantrakorn K; Tassaneeyakul W; Tiamkao S; Jantararoungtong T; Prabmechai N; Vannaprasaht S; Chumworathayi P; Chen P; Sritipsukho P
Pain Pract; 2012 Mar; 12(3):202-8. PubMed ID: 21676164
[TBL] [Abstract][Full Text] [Related]
8. A study of HLA class I and class II 4-digit allele level in Stevens-Johnson syndrome and toxic epidermal necrolysis.
Cristallo AF; Schroeder J; Citterio A; Santori G; Ferrioli GM; Rossi U; Bertani G; Cassano S; Gottardi P; Ceschini N; Barocci F; Ribizzi G; Cutrupi V; Cairoli R; Rapisarda V; Pastorello EA; Barocci S
Int J Immunogenet; 2011 Aug; 38(4):303-9. PubMed ID: 21545408
[TBL] [Abstract][Full Text] [Related]
9. CD94/NKG2C is a killer effector molecule in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis.
Morel E; Escamochero S; Cabañas R; Díaz R; Fiandor A; Bellón T
J Allergy Clin Immunol; 2010 Mar; 125(3):703-10, 710.e1-710.e8. PubMed ID: 20132973
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetics of toxic epidermal necrolysis.
Lee MT; Hung SI; Wei CY; Chen YT
Expert Opin Pharmacother; 2010 Sep; 11(13):2153-62. PubMed ID: 20536296
[TBL] [Abstract][Full Text] [Related]
11. Human leukocyte antigens and drug hypersensitivity.
Chung WH; Hung SI; Chen YT
Curr Opin Allergy Clin Immunol; 2007 Aug; 7(4):317-23. PubMed ID: 17620823
[TBL] [Abstract][Full Text] [Related]
12. Stevens-Johnson syndrome and toxic epidermal necrolysis.
Harr T; French LE
Chem Immunol Allergy; 2012; 97():149-66. PubMed ID: 22613860
[TBL] [Abstract][Full Text] [Related]
13. Pathogenesis and recent therapeutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis.
Khalili B; Bahna SL
Ann Allergy Asthma Immunol; 2006 Sep; 97(3):272-80; quiz 281-3, 320. PubMed ID: 17042130
[TBL] [Abstract][Full Text] [Related]
14. Genetic predisposition of life-threatening antiepileptic-induced skin reactions.
Chung WH; Hung SI; Chen YT
Expert Opin Drug Saf; 2010 Jan; 9(1):15-21. PubMed ID: 20001755
[TBL] [Abstract][Full Text] [Related]
15. [Stevens-Johnson syndrome and toxic epidermal necrolysis--updates and innovations].
Halevy S
Harefuah; 2010 Mar; 149(3):186-90, 193. PubMed ID: 20684173
[TBL] [Abstract][Full Text] [Related]
16. Stevens-Johnson syndrome and toxic epidermal necrolysis.
Borchers AT; Lee JL; Naguwa SM; Cheema GS; Gershwin ME
Autoimmun Rev; 2008 Sep; 7(8):598-605. PubMed ID: 18603022
[TBL] [Abstract][Full Text] [Related]
17. Distinguishing between erythema multiforme major and Stevens-Johnson syndrome/toxic epidermal necrolysis immunopathologically.
Iwai S; Sueki H; Watanabe H; Sasaki Y; Suzuki T; Iijima M
J Dermatol; 2012 Sep; 39(9):781-6. PubMed ID: 22458564
[TBL] [Abstract][Full Text] [Related]
18. Immunologic Mediators in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.
Saeed HN; Chodosh J
Semin Ophthalmol; 2016; 31(1-2):85-90. PubMed ID: 26959133
[TBL] [Abstract][Full Text] [Related]
19. Oxcarbazepine-induced Stevens-Johnson syndrome: a case report.
Lin LC; Lai PC; Yang SF; Yang RC
Kaohsiung J Med Sci; 2009 Feb; 25(2):82-6. PubMed ID: 19321411
[TBL] [Abstract][Full Text] [Related]
20. Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand.
Abe R; Shimizu T; Shibaki A; Nakamura H; Watanabe H; Shimizu H
Am J Pathol; 2003 May; 162(5):1515-20. PubMed ID: 12707034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
